The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review
- 1 July 2003
- journal article
- review article
- Published by Elsevier in Thrombosis Research
- Vol. 109, S9-S15
- https://doi.org/10.1016/s0049-3848(03)00249-4
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation: SPORTIF ii: a dose-guiding, tolerability, and safety studyJournal of the American College of Cardiology, 2003
- Pharmacokinetics of Melagatran and the Effect on Ex Vivo Coagulation Time in Orthopaedic Surgery Patients Receiving Subcutaneous Melagatran and Oral XimelagatranClinical Pharmacokinetics, 2003
- No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor XimelagatranClinical Pharmacokinetics, 2003
- No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male VolunteersClinical Pharmacokinetics, 2003
- Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin InhibitorClinical Pharmacokinetics, 2003
- DalteparinDrugs, 2000
- Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drugBiopharmaceutics & Drug Disposition, 1998
- Trial of Different Intensities of Anticoagulation in Patients with Prosthetic Heart ValvesNew England Journal of Medicine, 1990
- Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1982
- HYPOPROTHROMBINqMIA PRODUCED BY METHYLENE-BIS-(HYDROXYCOUMARIN) *1ITS USE IN THROMBOSISThe Lancet, 1942